Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
Published in the Commonwealth of Australia Gazette 1999
Therapeutic Goods Act 1989
I, GRANT TAMBLING, Parliamentary Secretary to the Minister for Health and Aged Care, on behalf of the Minister for Health and Aged Care and under subsection 17 (5) of the Therapeutic Goods Act 1989, require the following therapeutic goods to be included in the part of the Australian Register of Therapeutic Goods for listed goods:
- therapeutic goods containing sodium selenite, selenomethionine, selenocysteine or high selenium yeast as an active ingredient (or any combination of them) and that, for subsection 16 (1) of the Act, are distinct therapeutic goods by reason of having directions for use stating that the goods contain selenium and warning:
- that selenium is toxic in high doses; and
- that selenium in dietary supplements should not exceed a daily dose of 100 µg: and
- that goods containing selenium are not suitable for use by children under the age of 15 years;
- therapeutic goods containing Bifidobacterium longum strain BB536 as an active ingredient;
- therapeutic goods containing beta-hydroxy-beta-methylbutyric acid, calcium beta-hvdroxy-beta-methylbutyrate or sodium beta-hydroxy-beta-methylbutyrate as an active ingredient (or any combination of them).
Dated 18 June 1999
Parliamentary Secretary to the Minister for Health and Aged Care